Acelyrin, Inc Common Stock Performance
SLRN Stock | USD 4.55 0.02 0.44% |
ACELYRIN, INC has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.13, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ACELYRIN, INC will likely underperform. ACELYRIN, INC Common at this moment shows a risk of 5.14%. Please confirm ACELYRIN, INC Common potential upside, and the relationship between the total risk alpha and kurtosis , to decide if ACELYRIN, INC Common will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in ACELYRIN, INC Common are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, ACELYRIN, INC may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
Actual Historical Performance (%)
One Day Return (0.44) | Five Day Return (4.81) | Year To Date Return (42.70) | Ten Year Return (74.72) | All Time Return (74.72) |
1 | ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 12 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Pr... | 09/10/2024 |
2 | Disposition of tradable shares by Labrucherie Gil M of ACELYRIN, INC subject to Rule 16b-3 | 09/13/2024 |
3 | Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12 | 09/25/2024 |
4 | Vanguard Group Incs Strategic Reduction in Acelyrin Inc Shares | 11/05/2024 |
5 | Insider Trading | 11/13/2024 |
6 | Acelyrin Inc Q3 2024 Earnings Call Highlights Strategic Pipeline Refocus and Financial ... | 11/14/2024 |
7 | Acquisition by Murugan Amar of 525000 shares of ACELYRIN, INC at 4.73 subject to Rule 16b-3 | 11/25/2024 |
Begin Period Cash Flow | 267.1 M |
ACELYRIN, |
ACELYRIN, INC Relative Risk vs. Return Landscape
If you would invest 457.00 in ACELYRIN, INC Common on September 2, 2024 and sell it today you would lose (2.00) from holding ACELYRIN, INC Common or give up 0.44% of portfolio value over 90 days. ACELYRIN, INC Common is currently generating 0.1221% in daily expected returns and assumes 5.1395% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than ACELYRIN,, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
ACELYRIN, INC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ACELYRIN, INC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ACELYRIN, INC Common, and traders can use it to determine the average amount a ACELYRIN, INC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0238
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | SLRN | Huge Risk |
Negative Returns |
Estimated Market Risk
5.14 actual daily | 45 55% of assets are more volatile |
Expected Return
0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average ACELYRIN, INC is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ACELYRIN, INC by adding it to a well-diversified portfolio.
ACELYRIN, INC Fundamentals Growth
ACELYRIN, Stock prices reflect investors' perceptions of the future prospects and financial health of ACELYRIN, INC, and ACELYRIN, INC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ACELYRIN, Stock performance.
Return On Equity | -0.42 | ||||
Return On Asset | -0.33 | ||||
Current Valuation | (99.33 M) | ||||
Shares Outstanding | 100.33 M | ||||
Price To Book | 0.86 X | ||||
EBITDA | (381.53 M) | ||||
Net Income | (381.64 M) | ||||
Total Debt | 1.19 M | ||||
Book Value Per Share | 5.29 X | ||||
Cash Flow From Operations | (169.71 M) | ||||
Earnings Per Share | (2.46) X | ||||
Market Capitalization | 458.49 M | ||||
Total Asset | 742.69 M | ||||
Retained Earnings | (488.72 M) | ||||
Working Capital | 651.48 M | ||||
About ACELYRIN, INC Performance
By examining ACELYRIN, INC's fundamental ratios, stakeholders can obtain critical insights into ACELYRIN, INC's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that ACELYRIN, INC is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.51) | (0.54) | |
Return On Capital Employed | (0.64) | (0.67) | |
Return On Assets | (0.51) | (0.54) | |
Return On Equity | (0.58) | (0.55) |
Things to note about ACELYRIN, INC Common performance evaluation
Checking the ongoing alerts about ACELYRIN, INC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ACELYRIN, INC Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.ACELYRIN, INC Common had very high historical volatility over the last 90 days | |
ACELYRIN, INC Common has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (381.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
ACELYRIN, INC generates negative cash flow from operations | |
ACELYRIN, INC Common has a poor financial position based on the latest SEC disclosures | |
Over 99.0% of the company shares are owned by institutional investors | |
Latest headline from MacroaxisInsider: Acquisition by Murugan Amar of 525000 shares of ACELYRIN, INC at 4.73 subject to Rule 16b-3 |
- Analyzing ACELYRIN, INC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ACELYRIN, INC's stock is overvalued or undervalued compared to its peers.
- Examining ACELYRIN, INC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ACELYRIN, INC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ACELYRIN, INC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ACELYRIN, INC's stock. These opinions can provide insight into ACELYRIN, INC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in ACELYRIN, INC Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACELYRIN, INC. If investors know ACELYRIN, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACELYRIN, INC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.33) | Return On Equity (0.42) |
The market value of ACELYRIN, INC Common is measured differently than its book value, which is the value of ACELYRIN, that is recorded on the company's balance sheet. Investors also form their own opinion of ACELYRIN, INC's value that differs from its market value or its book value, called intrinsic value, which is ACELYRIN, INC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACELYRIN, INC's market value can be influenced by many factors that don't directly affect ACELYRIN, INC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACELYRIN, INC's value and its price as these two are different measures arrived at by different means. Investors typically determine if ACELYRIN, INC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACELYRIN, INC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.